Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480210 | 1.00 | EPHX2 (0.60) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL24575927 | 0.92 | EPHX2 (0.64) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL14025088 | 0.87 | EPHX2 (0.60) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL2692933 | 0.86 | EPHX2 (0.59) | EPHX2LMNAGAASSTR4TRPV1 | |
| SCHEMBL6514206 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 | |
| SCHEMBL6529748 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 | |
| SCHEMBL7263715 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 | |
| SCHEMBL8518963 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 | |
| SCHEMBL29609692 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 | |
| SCHEMBL9817975 | 0.83 | LMNA (0.61) | EPHX2LMNAGAASSTR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | EPHX2 2638/4885LMNA 2811/4885GAA 3192/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | EPHX2 1670/4885LMNA 4687/4885GAA 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.